Bi-Specific Fusion Proteins
AssigneeSilver Creek Pharmaceuticals, Inc.
InventorsUlrik Nielsen, Thomas Wickham, Birgit Schoeberl, Brian Harms, Bryan Linggi, Matthew Onsum, Byron DeLaBarre, Shaun M. Lippow
Life of this patent
Estimating the term…
Abstract
Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
Claims15
-20. (canceled)
A bi-specific fusion protein comprising:
- (a) Annexin V comprising an amino acid sequence having at least 99% identity with SEQ ID NO:
- 31, and
- (b) IGF-1 comprising an amino acid sequence having at least 98.5% identity with SEQ ID NO:
- 3.
A method for treating kidney tissue damage, the method comprising:
- administering to a subject in need thereof a therapeutically effective amount of a bi-specific fusion protein comprising Annexin V comprising an amino acid sequence having at least 99% identity with SEQ ID NO:
- 31, and IGF-1 comprising an amino acid sequence having at least 98.5% identity with SEQ ID NO:
- 3.
Dependencies are inferred from the claim text.